Lista de obras - Bertrand Leblond - Dominio Público Uruguay

2-difluoromethyloestrone 3-O-sulphamate, a highly potent steroid sulphatase inhibitor.

artículo científico publicado en 2004

2-substituted estradiol bis-sulfamates, multitargeted antitumor agents: synthesis, in vitro SAR, protein crystallography, and in vivo activity

artículo científico publicado en 2006

A novel DYRK1A (dual specificity tyrosine phosphorylation-regulated kinase 1A) inhibitor for the treatment of Alzheimer's disease: effect on Tau and amyloid pathologies in vitro.

artículo científico publicado en 2015

An Unusual Binding Model of the Methyl 9-Anilinothiazolo[5,4-f] quinazoline-2-carbimidates (EHT 1610 and EHT 5372) Confers High Selectivity for Dual-Specificity Tyrosine Phosphorylation-Regulated Kinases

artículo científico publicado en 2016

Anti-cancer activities of novel D-ring modified 2-substituted estrogen-3-O-sulfamates.

artículo científico publicado en 2005

DYRK1A controls the transition from proliferation to quiescence during lymphoid development by destabilizing Cyclin D3

artículo científico publicado en 2015

Design and synthesis of thiazolo[5,4-f]quinazolines as DYRK1A inhibitors, part I.

artículo científico publicado en 2014

Design and synthesis of thiazolo[5,4-f]quinazolines as DYRK1A inhibitors, part II.

artículo científico publicado en 2014

Growth inhibition of human in vitro and mouse in vitro and in vivo mammary tumor models by retinoids in comparison with tamoxifen and the RU-486 anti-progestagen.

artículo científico publicado en 1998

Inhibition of superoxide dismutase by 2-methoxyoestradiol analogues and oestrogen derivatives: structure-activity relationships.

artículo científico publicado en 2001

Inhibitors of tripeptidyl peptidase II. 3. Derivation of butabindide by successive structure optimizations leading to a potential general approach to designing exopeptidase inhibitors.

artículo científico publicado en 2005

Phosphorylation of CLEC-2 is dependent on lipid rafts, actin polymerization, secondary mediators, and Rac.

artículo científico publicado en 2010

RAC1 inhibition targets amyloid precursor protein processing by gamma-secretase and decreases Abeta production in vitro and in vivo.

artículo científico publicado en 2005

Rap1-Rac1 circuits potentiate platelet activation

artículo científico publicado en 2011

Recovery of dopamine neuronal transporter but lack of change of its mRNA in substantia nigra after inactivation by a new irreversible inhibitor characterized in vitro and ex vivo in the rat.

artículo científico publicado en 1999

Specificity and mechanism of action of EHT 1864, a novel small molecule inhibitor of Rac family small GTPases.

artículo científico publicado en 2007

Structure-activity relationship of isoform selective inhibitors of Rac1/1b GTPase nucleotide binding.

artículo científico publicado en 2009

Synthesis and evaluation of analogues of estrone-3-O-sulfamate as potent steroid sulfatase inhibitors

artículo científico publicado en 2012

Vascular disrupting activity and the mechanism of action of EHT 6706, a novel anticancer tubulin polymerization inhibitor.

artículo científico publicado en 2012

Lista de obras de Bertrand Leblond

2-difluoromethyloestrone 3-O-sulphamate, a highly potent steroid sulphatase inhibitor.

2-substituted estradiol bis-sulfamates, multitargeted antitumor agents: synthesis, in vitro SAR, protein crystallography, and in vivo activity

A novel DYRK1A (dual specificity tyrosine phosphorylation-regulated kinase 1A) inhibitor for the treatment of Alzheimer's disease: effect on Tau and amyloid pathologies in vitro.

An Unusual Binding Model of the Methyl 9-Anilinothiazolo[5,4-f] quinazoline-2-carbimidates (EHT 1610 and EHT 5372) Confers High Selectivity for Dual-Specificity Tyrosine Phosphorylation-Regulated Kinases

Anti-cancer activities of novel D-ring modified 2-substituted estrogen-3-O-sulfamates.

DYRK1A controls the transition from proliferation to quiescence during lymphoid development by destabilizing Cyclin D3

Design and synthesis of thiazolo[5,4-f]quinazolines as DYRK1A inhibitors, part I.

Design and synthesis of thiazolo[5,4-f]quinazolines as DYRK1A inhibitors, part II.

Growth inhibition of human in vitro and mouse in vitro and in vivo mammary tumor models by retinoids in comparison with tamoxifen and the RU-486 anti-progestagen.

Inhibition of superoxide dismutase by 2-methoxyoestradiol analogues and oestrogen derivatives: structure-activity relationships.

Inhibitors of tripeptidyl peptidase II. 3. Derivation of butabindide by successive structure optimizations leading to a potential general approach to designing exopeptidase inhibitors.

Phosphorylation of CLEC-2 is dependent on lipid rafts, actin polymerization, secondary mediators, and Rac.

RAC1 inhibition targets amyloid precursor protein processing by gamma-secretase and decreases Abeta production in vitro and in vivo.

Rap1-Rac1 circuits potentiate platelet activation

Recovery of dopamine neuronal transporter but lack of change of its mRNA in substantia nigra after inactivation by a new irreversible inhibitor characterized in vitro and ex vivo in the rat.

Specificity and mechanism of action of EHT 1864, a novel small molecule inhibitor of Rac family small GTPases.

Structure-activity relationship of isoform selective inhibitors of Rac1/1b GTPase nucleotide binding.

Synthesis and evaluation of analogues of estrone-3-O-sulfamate as potent steroid sulfatase inhibitors

Vascular disrupting activity and the mechanism of action of EHT 6706, a novel anticancer tubulin polymerization inhibitor.